13 Habits Of Couples Who Secretly Can't Stand Each Other
1. Communication Is Practically Nonexistent
You barely talk anymore, at least not about anything meaningful. Your conversations are reduced to logistics—who's picking up the kids, what's for dinner, or how you need milk. When was the last time you sat down and talked about how you're feeling or what your future holds? Dr. John Gottman, a leading researcher in marital stability, emphasizes the importance of communication for relationship satisfaction. If you can't even remember the last time you had a heart-to-heart, it might be time to reassess.
And it's not just about talking; it's about listening too. You find yourself tuning out when your partner speaks, or maybe they're the one scrolling through their phone during conversations. Feeling unheard can lead to resentment and an emotional disconnect. Over time, this habit of not genuinely communicating turns into a quiet wall between you. Ignoring this wall only makes it grow taller and thicker.
2. Affection Is Sparse Or Forced
Remember when you couldn't keep your hands off each other? Now, the only physical contact you have is a quick peck on the cheek or a half-hearted hug. If affection starts to feel obligatory or like a chore, something is definitely off. You might even cringe when your partner reaches for you, which isn't exactly a sign of love and adoration. Touch should feel natural, not like you're checking off a box.
You might say you're just not a "touchy" person, but the truth is, you were at some point in the relationship. Over time, a lack of affection can lead to a lack of intimacy and connection. This could create a vicious cycle where you feel even less inclined to be affectionate. A little effort to reconnect physically can go a long way. Don't let inertia take away one of the simplest forms of connection.
3. Constant Criticism
Do you find yourself criticizing your partner more often than praising them? Moments that were once quirky and lovable now get on your last nerve. According to Dr. Harriet Lerner, a clinical psychologist, criticism is often an expression of our unmet needs. You might be voicing criticisms when you're actually yearning for something more from the relationship. Take a moment to consider if those complaints are masking deeper concerns.
Criticism isn't just about what you say; it's also how you say it. Your tone might be short, and your words might sting more than intended. Over time, constant criticism can erode self-esteem and breed resentment. This negativity can become the lens through which you see each other. To avoid this, focus on expressing your needs in a positive way rather than pointing out flaws.
4. Avoidance Of Conflict
You might think that avoiding fights is a sign of a healthy relationship, but it can be quite the opposite. If you're consistently dodging disagreements, you're not addressing the issues that matter. Pretending problems don't exist doesn't make them go away. In fact, it often makes them bigger and more unmanageable down the line. Conflict is not inherently bad; it can be a catalyst for growth and understanding.
Avoidance can lead to simmering tensions just beneath the surface. You might find yourself feeling anxious or walking on eggshells, worrying that any moment could lead to an explosion. Unresolved issues are like ticking time bombs; they might stay dormant for a while, but they will eventually blow up. Healthy conflict involves airing out issues in a constructive manner. Don't shy away from it; embrace it as a necessary part of any relationship.
5. Public Displays Of Disinterest
While some couples can't keep their hands off each other in public, you barely acknowledge each other's presence. You might be together, but you act more like acquaintances than partners. According to Dr. Terri Orbuch, a psychologist known as The Love Doctor, couples who show affection in public tend to have more satisfied relationships. It's not about putting on a show for others; it's about genuinely enjoying each other's company. If you can't remember the last time you held hands or exchanged a loving glance, it might be worth exploring why.
This kind of detachment is often more noticeable to outsiders than to the couple themselves. Friends and family might see your lack of interaction and wonder what's going on. The absence of affectionate gestures in public can be a reflection of what's happening behind closed doors. It's an indication that you're not as connected as you once were. Take note of these signs and consider what they mean for your relationship.
6. Social Media Facades
On social media, you're the picture-perfect couple. You post about date nights, anniversaries, and loving moments, but it feels more like a performance than reality. Behind the scenes, you're barely speaking, and your interactions are minimal. The contrast between your digital life and your real life can be jarring. It's a sign that you're more concerned about appearances than actual happiness.
This facade can be exhausting to maintain. You might even feel pressure to live up to the idealized version of your relationship that you've created online. When the likes and comments fade, you're left with the reality that things aren't as rosy as they seem. It's crucial to focus on the genuine connection rather than the perceived one. After all, likes and comments won't keep a relationship afloat.
7. Separate Social Circles
You've cultivated your own social circles, and they rarely overlap. It's not just about having different friends; it's about living parallel lives. Dr. Lisa Firestone, a clinical psychologist, suggests that maintaining separate social lives can indicate a lack of shared interests and goals. While it's healthy to have individual pursuits, there should also be room for shared experiences. If you're consistently going solo to events, it might be a sign that your lives are drifting apart.
Your social life should ideally be a mix of togetherness and independence. If your partner never invites you to hang out with their friends or vice versa, it could signal a deeper disconnect. Over time, this separation can lead to feelings of isolation from each other. It's important to make an effort to engage with each other's social circles to maintain a sense of unity. Don't let separate lives create a wedge between you.
8. Reluctance To Make Future Plans
Talking about the future feels like a no-go zone. The idea of planning a trip together or even discussing where you'll be in a year gives you pause. It's as if you're living in the now because the future seems too uncertain or daunting to consider. When couples are truly connected, they look forward to creating a shared future. If you're avoiding these discussions, it might be a sign that you're not on the same page about your long-term goals.
A reluctance to plan ahead often indicates a lack of confidence in the relationship's longevity. You might find yourself thinking, "What's the point in planning if we might not even be together?" This mindset can prevent you from investing emotionally and mentally in the relationship. Without future plans, there's little to work toward together. It's essential to address this and figure out what's holding you back from looking ahead.
9. Lack Of Emotional Support
When things get tough, your partner is not the first person you turn to. You either handle it on your own or seek support from friends and family instead. If you're not comfortable seeking emotional support from your partner, it's a significant red flag. Ideally, your partner should be your confidant and cheerleader. When that's missing, it's hard to feel connected or supported.
This lack of support can create a feeling of loneliness even when you're together. Your partner might seem indifferent or uninterested in what you're going through. Over time, this can weaken the emotional bond that holds you together. It's essential to feel that your partner is there for you in challenging times. If that's not the case, it's important to have a conversation about how you can both be more supportive.
10. One-Sided Decision Making
One of you is making all the decisions, big and small, while the other just goes along for the ride. This might be convenient in the short term, but it's not sustainable for a balanced relationship. If one partner always calls the shots, it can lead to a power imbalance. This dynamic might stem from a lack of interest or investment by one partner, which only breeds resentment over time. A relationship should be a partnership, not a dictatorship.
When one person is consistently sidelined in decision-making, it can lead to feelings of insignificance. You might start to feel like your opinions and desires don't matter. This can diminish your sense of self-worth and importance in the relationship. To maintain balance, it's critical to involve each other in decisions and value each other's input. A healthy relationship thrives on mutual respect and collaboration.
11. Avoiding Time Together
You find reasons to be apart more often than together. Whether it's working late, taking on extra hobbies, or hanging out with friends more often, time together has taken a backseat. It's as if you're intentionally filling your calendar to avoid quality time as a couple. While alone time is important, consistently avoiding togetherness is a red flag. It suggests that being in each other's presence is something you're avoiding rather than cherishing.
Over time, this avoidance can lead to an emotional distance that's hard to bridge. You might find yourself feeling like strangers living under the same roof. The less time you spend together, the less opportunity there is to connect and understand each other's world. Making an effort to prioritize time together can help rekindle the relationship. Don't let busyness become an excuse for neglecting your partnership.
12. Frequent Comparison To Others
You frequently find yourself comparing your relationship to others, often feeling like yours falls short. Whether it's your friends' relationships or the couples you see online, the grass always seems greener. This habit can breed dissatisfaction and unspoken resentment. Frequently comparing your partnership to others is a sure way to undermine it. It's important to remember that every relationship has its unique dynamics and challenges.
This tendency to compare can make you blind to the good things in your own relationship. You might focus so much on what you lack that you forget to appreciate what you have. Over time, this can lead to a sense of inadequacy and frustration. It's crucial to focus on your unique journey and not get caught up in what others have. Emphasizing gratitude can shift your perspective and create a more positive outlook.
13. Playing The Blame Game
Whenever something goes wrong, your first instinct is to point fingers. Blame becomes the default rather than looking for constructive solutions. This kind of behavior creates a toxic atmosphere that makes resolving issues near impossible. Constant blame can diminish compassion and empathy in the relationship. Instead of working as a team to tackle challenges, you end up on opposite sides.
Blame can also lead to defensiveness, which stalls any chance of productive communication. When both partners feel attacked, they're less likely to open up and be vulnerable. This creates an environment where issues never really get resolved, just swept under the rug. A more constructive approach involves focusing on problem-solving rather than fault-finding. Shifting this mindset can lead to healthier interactions and a stronger relationship.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
4 minutes ago
- CNN
NIH director lays out agency's research and funding priorities in new strategy statement
The director of the US National Institutes of Health outlined on Friday a 'unified strategy' to align the agency's priorities and funding, a move he said was meant to offer clarification following sweeping changes at the agency, including massive budget cuts, grant cancellations and plans for reorganization. In Friday's statement, Dr. Jay Bhattacharya emphasized the need for transparency with the taxpaying American public and an intent to 'honor their trust.' He identified key priorities for the NIH, including chronic disease and nutrition – as per an executive order 'on Gold-Standard Science and the Make America Healthy Again Commission Report' – as well as artificial intelligence, alternative testing models and real-world data platforms. He also noted that the agency is dedicated to supporting research that pursues 'innovative, and sometimes controversial, questions.' NIH funding decisions will reflect these priorities and other 'core principles,' the statement said. 'As stewards of taxpayer funds, NIH must deliver results that matter to the public,' Bhattacharya wrote. 'Through this strategy, we will better leverage the synergistic missions of each NIH Institute and Center to fund the most meritorious science, address urgent health needs, and sustain a robust biomedical research workforce.' More details were shared on certain agency priorities with an intent to 'clarify specific issues that currently require additional guidance,' the statement said, including autism, nutrition, HIV/AIDS, research on racial disparities, transgender care and more. In April, a policy note from the NIH said the agency can pull medical research funding from universities with diversity and inclusion programs. Friday's statement noted that the NIH was 'shifting to solution-oriented approaches in health disparities research.' 'In contrast to research that considers race or ethnicity when scientifically justified […] research based on ideologies that promote differential treatment of people based on race or ethnicity, rely on poorly defined concepts or on unfalsifiable theories, does not follow the principles of gold-standard science,' the statement read. NIH also intends to prioritize research focused on what it called 'more promising avenues of research' for the the health of transgender youth than studies involving treatments such as puberty suppression, hormone therapy or surgery. 'Research that aims to identify and treat the harms these therapies and procedures have potentially caused to minors diagnosed with gender dysphoria, gender identity disorder, or gender incongruence, and how to best address the needs of these individuals so that they may live long, healthy lives is more promising,' the statement said. Multiple priorities emphasize a preference for domestic research, including a new system to manage projects with funding for foreign research institutions and a blueprint for domestic training programs. NIH will also prioritize research that can be replicated or reproduced. 'We are exploring various mechanisms to support scientists focused on replication work, to publish negative findings, and to elevate replication research,' the statement read.
CNN
34 minutes ago
- CNN
Hundreds may have been exposed to rabies at bat-infested cabins in Grand Teton National Park
FacebookTweetLink Health officials are working to alert hundreds of people in dozens of states and several countries who may have been exposed to rabies in bat-infested cabins in Wyoming's Grand Teton National Park over the past few months. As of Friday, none of the bats found in some of the eight linked cabins at Jackson Lake Lodge had tested positive for rabies. But the handful of dead bats found and sent to the Wyoming State Veterinary Laboratory in Laramie for testing were probably only a small sample of the likely dozens that colonized the attic above the row of cabins, Wyoming State Health Officer Dr. Alexia Harrist said. Other bats weren't killed but got shooed out through cabin doors and windows. Meanwhile, the vast majority never flapped down from the attic into living spaces. Health officials thus deemed it better safe than sorry to alert everybody who has stayed in the cabins recently that they might have been exposed by being bitten or scratched. Especially when people are sleeping, a bat bite or scratch can go unseen and unnoticed. 'What we're really concerned about is people who saw bats in their rooms and people who might have had direct contact with a bat,' Harrist said Friday. The cabins have been unoccupied, with no plans to reopen, since concessionaire Grand Teton Lodge Company discovered the bat problem July 27. Bats are a frequent vector of the rabies virus. Once symptoms occur — muscle aches, vomiting, itching, to name a few — rabies is almost always fatal in humans. The good news is a five-shot prophylactic regimen over a two-week period soon after exposure is highly effective in preventing illness, Harrist noted. The cabins opened for the summer season in May after being vacant over the winter. Based on the roughly 250 reservations through late July, health officials estimated that up to 500 people had stayed in the cabins. They were trying to reach people in 38 states and seven countries through those states' health agencies and, in the case of foreign visitors, the U.S. Centers for Disease Control and Prevention. Others who have not been alerted yet but stayed in cabins 516, 518, 520, 522, 524, 526, 528 and 530 this year should tell health officials or a doctor immediately, Harrist said. Health officials were recommending prophylactic shots for people who fit certain criteria, such as deep sleepers who found a bat in their room, and children too young to say that they had seen a bat. The Wyoming Department of Health had no ongoing concern about visitor safety at the Jackson Lake Lodge area. That includes a Federal Reserve economic policy symposium Aug. 21-23 that takes place at Jackson Lake Lodge every summer. 'The lodge company has done a fantastic job of doing their due diligence of making sure everyone that is coming in for that, and for all other visits this year, are going to be as safe as possible,' said Emily Curren, Wyoming's public health veterinarian. 'Three or four' dead bats from the cabins tested negative and one that was mangled did not have enough brain tissue to be testable, Curren said. All were brown bats, which come in two species: 'little' and 'big,' with the larger ones more than twice as big. Officials were unsure which species these were, but both are common in Wyoming. They typically live in colonies of 30 to 100 individuals, Curren said. 'That's a lot of bats that we cannot rule out a risk of rabies being in,' Curren said. 'There's no way for us to know for certain about every single bat that got into these rooms.' There are no plans to exterminate the bats, Grand Teton National Park spokesperson Emily Davis said. Devices fitted to the building were keeping the bats from getting back in after flying out in pursuit of insects to eat, they said.
Yahoo
35 minutes ago
- Yahoo
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced calorie diet and increased physical activity1 The accelerated approval is based on Part 1 of the ESSENCE trial, in which Wegovy® demonstrated a statistically significant improvement in liver fibrosis (liver scarring) with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo1,2 Wegovy® is also indicated, along with a reduced calorie diet and increased physical activity, to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight, and for adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off1 PLAINSBORO, N.J., Aug. 15, 2025 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® (semaglutide) injection 2.4 mg, making it the first and only glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced calorie diet and increased physical activity.1 This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.1 This FDA approval is based on results from the phase 3 ESSENCE trial investigating the effects of once-weekly Wegovy® 2.4 mg injection on liver histology in adults with MASH and moderate to advanced liver fibrosis (stage F2 to F3) at Week 72. The first primary endpoint showed 63% of people treated with Wegovy® 2.4 mg injection (n=534) achieved resolution of steatohepatitis and no worsening of liver fibrosis compared to 34% on placebo (n=266) with a statistically significant difference in response rate vs placebo of 29 (95% CI, 21;36). Additionally, the second primary endpoint showed 37% of people treated with Wegovy® 2.4 mg achieved improvement in liver fibrosis and no worsening of steatohepatitis compared to 22% on placebo with a statistically significant difference in response rate vs placebo of 14 (95% CI, 8;21). A confirmatory secondary endpoint at Week 72 showed 33% of patients treated with Wegovy® 2.4 mg achieved both resolution of steatohepatitis and improvement in liver fibrosis compared to 16% on placebo with a statistically significant difference in response rate vs placebo of 17 (95% CI, 10;23). A total of 83.5% of the patients in the semaglutide group maintained the target dose of 2.4 mg until Week 72.1,2 "Today's decision by the FDA reflects the continued progress in how we understand and treat patients with MASH, bringing us closer to care that meets the needs of people living with this disease," said Arun Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University. "If left untreated, MASH can lead to serious and potentially fatal outcomes. The clinical evidence seen in ESSENCE underscores the promise of this approach to treating adults with MASH with moderate to advanced liver fibrosis." MASH represents a significant health burden in the US, affecting approximately one in 20 people.3 People living with MASH are often asymptomatic or present with nonspecific symptoms in the early stages of the disease, which may result in a delayed diagnosis.4 Left untreated, MASH can progress to serious and even fatal outcomes, such as cirrhosis, liver cancer, and the need for liver transplant.5 Among people who are living with overweight or obesity worldwide, one in three also have MASH.6 "For far too long, this disease has remained unrecognized, undiagnosed, and often untreated, despite impacting so many people," said Dave Moore, executive vice president of US Operations, at Novo Nordisk. "The FDA's conditional approval of Wegovy® for the treatment of adults with noncirrhotic MASH marks a truly pivotal milestone and a significant step forward for the MASH community and those seeking new options. This builds on the expanding body of evidence demonstrating the clinical benefits of semaglutide across a range of chronic conditions including diabetes, obesity, cardiovascular and chronic kidney disease." The FDA initially approved Wegovy® in 2021 with a reduced calorie meal plan and increased physical activity to help adults with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off. The indication was expanded in 2022 to include children aged 12 years and older with obesity. In 2024, Wegovy® was approved to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and either obesity or overweight.1 Today, the FDA has granted accelerated approval for Wegovy® for a new patient population to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. In February 2025, Novo Nordisk also filed for regulatory approval in the EU, followed by regulatory submission in Japan in May 2025. About ESSENCE ESSENCE is a phase 3 trial evaluating the effect of once-weekly subcutaneous semaglutide 2.4 mg in adults with metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis (stage 2 or 3). It is a two-part trial where 1,197 participants were randomized 2:1 to receive semaglutide 2.4 mg or placebo, on top of standard of care for 240 weeks. Lifestyle counseling and management of coexisting diseases were recommended in alignment with guidelines. In Part 1, the primary objective was to demonstrate that treatment with semaglutide 2.4 mg improves liver histology compared with placebo in patients with MASH and fibrosis stage 2 or 3. In Part 2, which is ongoing, the primary objective is to demonstrate that treatment with semaglutide 2.4 mg lowers the risk of liver-related clinical events compared to placebo in adults with MASH and moderate to advanced liver fibrosis at 240 weeks.2,7 About Metabolic Dysfunction-Associated Steatohepatitis (MASH)MASH is a serious form of fatty liver disease, which can be potentially life-threatening if not properly managed.4 Among people who are living with overweight or obesity worldwide, approximately one in three also have MASH.6 Excess fat can build up in the liver, which, over time, can lead to inflammation and significant scarring of the liver.8 People living with MASH are often asymptomatic or present with nonspecific symptoms in the early stages of the disease, which may result in a delayed diagnosis.4 Approximately one in 20 people in the United States are living with MASH.3 The disease progresses to cirrhosis in an estimated 20% of cases.9 MASH is a leading cause of cirrhosis in adults in the US, and MASH-related cirrhosis is the second most common indication for liver transplants in the country.10 What is Wegovy®?WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity. to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH. to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight that may help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose excess body weight and keep the weight off Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. It is not known if Wegovy® is safe and effective: for the treatment of MASH in children under 18 years to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in children under 18 years for the treatment of long-term weight loss in children under 12 years Important Safety Information What is the most important information I should know about Wegovy®?Wegovy® may cause serious side effects, including: Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Do not use Wegovy® if: you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy® Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you: have or have had problems with your pancreas or kidneys have type 2 diabetes and a history of diabetic retinopathy have or have had depression, suicidal thoughts, or mental health issues are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation) are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant are breastfeeding or plan to breastfeed. It is not known if Wegovy® passes into your breast milk Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly. What are the possible side effects of Wegovy®?Wegovy® may cause serious side effects, including: inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back gallbladder problems. Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go away serious allergic reactions. Stop using Wegovy® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy® increased heart rate. Wegovy® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes depression or thoughts of suicide. You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other procedures The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat. Please click HERE for Wegovy® Prescribing Information and Medication Guide. About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at References Wegovy® (semaglutide) injection [package insert]. Plainsboro, NJ: Novo Nordisk Inc. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. doi:10.1056/NEJMoa2 413258 Younossi ZM, Mangla KK, Chandramouli AS, et al. Estimating the economic impact of comorbidities in patients with MASH and defining high-cost burden in patients with noncirrhotic MASH. Hepatol Commun. 2024;8(8):e0488. doi:10.1097/HC9.00000 00000000488 Allen AM, Charlton M, Cusi K, et al. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgrad Med. 2024;136(3):229-245. doi:10.1080/00325481.2024.2325332 Kugelmas M, Noureddin M, Gunn N, et al. The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis. Liver Int. 2023;43(5):964-974. doi:10.1111/liv.15555 Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20-30. doi:10.1016/S2468-1253(22)00317-X Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther. 2024;60(11-12):1525-1533. doi:10.1111/apt.18331 National Institute of Diabetes and Digestive and Kidney Diseases. Definition & facts of NAFLD & NASH. Accessed June 13, 2025. Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(16):1619. doi:10.1001/jama.2020.5249 Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi:10.1002/hep.28431 Wegovy® is a registered trademark of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. All other trademarks, registered or unregistered, are the property of their respective owners. © 2025 Novo Nordisk All rights reserved. US25SN00042 August 2025 View original content to download multimedia: SOURCE NOVO NORDISK INC. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
